Skip to Main Content

A Phase 2 Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors

Conditions

Corpus Uteri | Larynx | Lung | Soft Tissue | Unknown Sites

Phase II

What is the purpose of this trial?

This is a multi-cohort, open-label, Phase 2 study designed to assess the clinical activity of sacituzumab govitecan in adult subjects with metastatic solid tumors with elevated Trop-2 expression.

  • Trial with
    Immunomedics, Inc.
  • Start Date
    10/27/2019
  • End Date
    04/29/2022
Trial Image

For more information about this study, contact:

Lisa Baker

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    01/16/2020
  • Study HIC
    #2000025243